… Bogaard has received speaker fees from and served on advisory boards for Pfizer and
United Therapeutics. Dr. Condliffe has received speaker and/or conference travel fees from and/…

Objectives : The purpose of this study was to examine the relationship between changes in
pulmonary vascular resistance (PVR) and right ventricular ejection fraction (RVEF) and …

Pulmonary arterial hypertension (PAH) is a deadly disease in which vasoconstriction and
vascular remodeling both lead to a progressive increase in pulmonary vascular resistance. …

Background— The most important determinant of longevity in pulmonary arterial hypertension
is right ventricular (RV) function, but in contrast to experimental work elucidating the …

Severe forms of pulmonary arterial hypertension (PAH) are characterized by various degrees
of remodeling of the pulmonary arterial vessels, which increases the pulmonary vascular …

Patients diagnosed with coronavirus disease 2019 (COVID-19) become critically ill primarily
around the time of activation of the adaptive immune response. Here, we provide evidence …

… Dr Bogaard is supported by the Netherlands Cardiovascular Research Initiative: the Dutch
… Dr Bogaard received speaker fees or honoraria for consultations from Actelion, Bayer, Pfizer…

There is increasing recognition of the crucial role of the right ventricle (RV) in determining
functional status and prognosis in multiple conditions. The normal RV is anatomically and …

Pulmonary arterial hypertension (PAH) is a rare disorder with a poor prognosis. Deleterious
variation within components of the transforming growth factor-β pathway, particularly the …

Pulmonary arterial hypertension (PAH) is no longer an orphan disease. There are three
different classes of drugs for the treatment of PAH that are currently being used and an …